Linalyl acetate

Acute Toxicity: other routes

Administrative data

Endpoint:

acute toxicity: other routes

Type of information:

experimental study

Adequacy of study:

other information

Reliability:

2 (reliable with restrictions)

Rationale for reliability incl. deficiencies:

other: Well documented study report which meets basic scientific principles

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

1969

Report date:

1969

Materials and methods

Test guideline

Qualifier:

no guideline followed

Principles of method if other than guideline:

other: BASF-test according to internal SOP

GLP compliance:

no

Limit test:

no

Test material

Test material information

Constituent 1

Reference substance name:

Linalyl acetate

EC Number:

204-116-4

EC Name:

Linalyl acetate

Cas Number:

115-95-7

Molecular formula:

C12H20O2

IUPAC Name:

1,5-dimethyl-1-vinylhex-4-en-1-yl acetate

Details on test material:

- Name of test material (as cited in study report): 3,7-dimethyl-1,6-octadien-3-yl-acetate (linalyl acetate),
- Analytical purity: 95-99%
- Impurities (identity and concentrations): dihydrolinalyl acetate

Test animals

Species:

mouse

Strain:

not specified

Sex:

male/female

Details on test animals or test system and environmental conditions:

TEST ANIMALS
- Source: obtained from Kisslegg, Germany
- Weight at study initiation: 20-34 g

Administration / exposure

Route of administration:

intraperitoneal

Vehicle:

other: Traganth

Details on exposure:

2%, 8%, 10%, 20% and 30% aquaous solution; emulsion with Traganth

Doses:

200, 640, 800, 1000, 1250, 1600, 3200, 6400 µl/kg

No. of animals per sex per dose:

10 animals per dose (200; 640; 1600; 3200; 6400 µl/kg)
20 animals per dose (800; 1000; 1250 µl/kg)

Control animals:

no

Details on study design:

- Duration of observation period following administration: 14 days
- Necropsy of survivors performed: yes
- Other examinations performed: clinical signs, body weight (only at initiation of the experiment)

Results and discussion

Effect levels

Effect levels 1

Sex:

male/female

Dose descriptor:

LD50

Effect level:

ca. 720 mg/kg bw

Remarks on result:

other: Nominal value, calculated with density = 0.9 g/cm3

Effect levels 2

Sex:

male/female

Dose descriptor:

LD50

Effect level:

ca. 800 other: µl/kg bw

Mortality:

200 µl/kg: no deaths;
640 µl/kg: 3/10 (day 7), 4/10 (day 14);
800 µl/kg: 7/20 (day 7), 9/20 (day 14);
1000 µl/kg: 13/20 (day 7), 15/20 (day 14);
1250 µl/kg: 1/20 (48 hrs); 8/20 (day 7); 9/20 (day 14);
1600 µl/kg: 1/10 (24 hrs); 5/10 (day 7): 8/10 (day 14);
3200 µl/kg: 6/10 (24 hrs); 8/10 (day 7); 10/10 (day 14);
6400 µl/kg: 10/10 (24 hrs)

Clinical signs:

6400-3200 µl/kg: staggering gait; delayed agitation of hind legs; closed eyes; strubby coat; fitful breathing (dyspnoea); abdominal lateral position; twitches; late deaths
1600-200 µl/kg: staggering gait, improved respiration (dyspnoea); lantern flanks; twitches, cry of pain; closed or adhering eyes; delayed agitation of hind legs; saltation convulsions, abdominal lateral position, aggressiveness, late deaths

Body weight:

only initial body weights given (necessary for dosing)

Gross pathology:

intraabdominal adhesions

Any other information on results incl. tables

Lethality:

Dose (µl/kg bw)	Concentration (%)	Number of animals	Dead animals
			24 h	48 h	day7	day 14
200	2	10	0/10	0/10	0/10	0/10
640	8	10	0/10	0/10	3/10	4/10
800	8	20	0/20	0/20	7/20	9/20
1000	10	20	0/20	0/20	13/20	15/20
1250	10	20	0/20	1/20	8/20	9/20
1600	20	10	1/10	1/10	5/10	8/10
3200	30	10	6/10	6/10	8/10	10/10
6400	30	10	10/10	10/10	10/10	10/10